Практическая значимость измерения уровня липопротеида(а) для стратификации риска

A. M. Namitokov; V. K. Zafiraki; S. V.  Kruchinova; O. P. Ishevskaya; E. D. Kosmacheva

doi:10.34687/2219-8202.JAD.2022.02.0003

Authors

A. M. Namitokov https://orcid.org/0000-0002-5866-506X
V. K. Zafiraki
S. V. Kruchinova
O. P. Ishevskaya
E. D. Kosmacheva

DOI:

https://doi.org/10.34687/2219-8202.JAD.2022.02.0003

Keywords:

lipoprotein(a), cardiovascular diseases, dyslipidemia.

Abstract

Lipoprotein(a) [Lp(a)] is a major risk factor of premature cardiovascular diseases that is rarely used in clinical practice. The increase in Lp(a)’s level measurement among target groups of population is a key to better risk stratification and enlargement of high and extremely high-risk groups. The absence of target medicines should not limit wide measurement of Lp(a).

Future investigations will lead to big changes in conventional contribution of Lp(a) in occurrence of premature cardiovascular diseases and new approaches of the pathological state pharmacological correction.

Downloads

Download data is not yet available.

References

Mortatility statistics in Russia. Статистика смертности в России. Accessed September 9, 2021. https://ripme.ru/article/statistika-smertnosti-v-rossii

Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):937-952. doi:10.1016/S0140-6736(04)17018-9

Приказ Министерства здравоохранения РФ от 1 июля 2015 г. №404ан “Об утверждении стандарта специализированной медицинской помощи при остром инфаркте миокарда (с подъемом сегмента ST электрокардиограммы).” Accessed August 17, 2021. https://minzdrav.gov.ru/documents/9229-prikaz-ministerstva-zdravoohraneniya-rf-ot-1-iyulya-2015-g-404an-ob-utver

Приказ Министерства здравоохранения РФ от 1 июля 2015 г. №405ан “Об утверждении стандарта специализированной медицинской помощи при нестабильной стенокардии, остром и повторном инфаркте миокарда (без подъема сегмента ST электрокардиограммы).” Accessed August 17, 2021. https://minzdrav.gov.ru/documents/9228-prikaz-ministerstvazdravoohraneniya-rf-ot-1-iyulya-2015-g405an-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi--pri-nestabilnoy-stenokardii-ostrom-i-povtornom-infarktemiokarda-bez-pod-ema-segmenta-st-elektrokardiogrammy

Diagnostics and correction of lipid metabolism disorders in order to prevent and treat of atherosclerosis. Russian recommendations, VII revision. Journal of atherosclerosis and dyslipidaemias. 2020;1(38):7-42. // Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-42. doi:10.34687/2219-8202.JAD.2020.01.0002

Berg K. A New Serum Type System In Man—The Lp System. Acta Pathologica Microbiologica Scandinavica. 1963;59(3):369-382. doi:10.1111/J.1699-0463.1963.TB01808.X

Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. Journal of Internal Medicine. 2013;273(1):6-30. doi:10.1111/J.1365-2796.2012.02592.X

Cook NR, Mora S, Ridker PM. Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. Journal of the American College of Cardiology. 2018;72(3):287-296. doi:10.1016/J.JACC.2018.04.060

Yin D, Shao P, Liu Y. Elevated lipoprotein (a) levels predict deep vein thrombosis in acute ischemic stroke patients. Neuroreport. 2016;27(1):39-44. doi:10.1097/WNR.0000000000000496

Shah NP, Pajidipati NJ, McGarrah RW, et al. Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. The American journal of cardiology. 2020;126:94-102. doi:10.1016/J.AMJCARD.2020.03.043

Kon V, Yang H, Fazio S. Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. Archives of medical research. 2015;46(5):379. doi:10.1016/J.ARCMED.2015.05.009

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111-188. doi:10.1093/EURHEARTJ/EHZ455

Afanas'eva OI, Ezhov MV, Pokrovskij SN. Analysis of the concentation of lipoprotein(a) in clinical practice: relevance and unsolved issues. Journal of atherosclerosis and dyslipidaemias. 2021;2(43):47–56 // Афанасьева ОИ, Ежов МВ, Покровский СН. Определение концентрации липопротеида(а) в клинической практике: актуальность и нерешенные вопросы. Атеросклероз и дислипидемии. 2021;2(43):47–56. DOI: 10.34687/2219-8202.JAD.2021.02.0004

O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483-1492. doi:10.1161/CIRCULATIONAHA.118.037184

Szarek M, Bittner VA, Aylward P, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal. 2020;41(44):4245-4255. doi:10.1093/EURHEARTJ/EHAA649

Forbes CA, Quek RGW, Deshpande S, et al. The relationship between Lp(a) and CVD outcomes: A systematic review. Lipids in Health and Disease. 2016;15(1). doi:10.1186/S12944-016-0258-8

Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart Journal. 2019;71(2):99-112. doi:10.1016/J.IHJ.2019.03.004

Forbes CA, Quek RGW, Deshpande S, et al. The relationship between Lp(a) and CVD outcomes: A systematic review. Lipids in Health and Disease. 2016;15(1).

Kamstrup PR. Lipoprotein(a) and Cardiovascular Disease. Clinical Chemistry. 2021;67(1):154-166. doi:10.1093/clinchem/hvaa247

Oo HP, Giovannucci J, O'Brien RC, Hare DL. The Prevalence of Elevated Lipoprotein(a) in Patients Presenting With Coronary Artery Disease. Heart, lung & circulation. 2020;29(11):1682-1687. doi:10.1016/J.HLC.2020.03.005

Qin S, Liu J, Jiang H, Hu B, Zhou Y, Olkkonen VM. Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: Meta-analysis of 9 cohort studies. Atherosclerosis. 2013;227(2):360-366. doi:10.1016/j.atherosclerosis.2013.01.014

Park SH, Rha SW, Choi BG, et al. Impact of high lipoprotein(a) levels on in-stent restenosis and long-term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug-eluting stents in Asian population. Clinical and experimental pharmacology & physiology. 2015;42(6):588-595. doi:10.1111/1440-1681.12396

Hoff HF, Beck GJ, Skibinski CI, Jürgens G, et al Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation. 1988 Jun;77(6):1238-44. doi: 10.1161/01.cir.77.6.1238.

Hoefler G, Harnoncourt F, Paschke E et al. Lipoprotein Lp(a). A risk factor for myocardial infarction. Arteriosclerosis (Dallas, Tex). 1988;8(4):398-401. doi:10.1161/01.ATV.8.4.398

Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339. doi:10.1001/JAMA.2009.801

Patel AP, Wang (汪敏先) M, Pirruccello JP, et al. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):465-474. doi: 10.1161/ATVBAHA.120.315291. Epub 2020 Oct 29. PMID: 33115266; PMCID: PMC7769893.

Børge G. Nordestgaard, M. John Chapman, et al, Lipoprotein(a) as a cardiovascular risk factor: current status, European Heart Journal, Volume 31, Issue 23, December 2010, Pages 2844–2853, https://doi.org/10.1093/eurheartj/ehq386